ストックスクリーナーアプリを入手
17.33
0.52%
0.1006
前日終値:
$17.23
開ける：
$17.11
24時間の取引高:
1.38M
Relative Volume:
0.78
時価総額：
$5.53B
収益：
$3.05B
当期純損益:
$181.32M
株価収益率:
46.46
EPS:
0.373
ネットキャッシュフロー:
$186.11M
1週間 パフォーマンス:
+7.51%
1か月 パフォーマンス:
+31.51%
6か月 パフォーマンス:
+34.16%
1年 パフォーマンス:
+113.04%
1日の値動き範囲:
$16.87
$17.43
1週間の範囲:
$15.93
$17.86
52週間の値動き範囲:
$7.665
$17.86
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
名前
Amneal Pharmaceuticals Inc
セクター
電話
908-947-3120
住所
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
17.32 | 5.50B | 3.05B | 181.32M | 186.11M | 0.373 |
TAK
Takeda Pharmaceutical Co Adr
|
15.91 | 50.27B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.31 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.28 | 38.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
73.67 | 31.90B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
545.85 | 23.03B | 3.17B | 1.29B | 1.01B | 27.09 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-17 | 開始されました | UBS | Buy |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-06-06 | 開始されました | Goldman | Buy |
| 2025-02-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-09-06 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | アップグレード | Goldman | Sell → Buy |
| 2020-12-14 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-12-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-07-27 | 開始されました | Goldman | Sell |
| 2020-05-12 | アップグレード | Guggenheim | Sell → Neutral |
| 2019-12-12 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2019-11-07 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 開始されました | Barclays | Equal Weight |
| 2019-05-21 | アップグレード | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2019-03-08 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | ダウングレード | SunTrust | Buy → Hold |
| 2018-08-13 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 開始されました | Morgan Stanley | Overweight |
| 2018-06-22 | 開始されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Amneal Pharmaceuticals Inc (AMRX) 最新ニュース
Amneal to Buy Kashiv for $375M Cash + 28.9M Shares (NASDAQ: AMRX) - Stock Titan
EMA Recommends Approval of Hopledo for Parkinson's Disease - Intellectia AI
Zambon and Amneal Receive Positive CHMP Opinion for Hopledo in Parkinson’s Disease in Europe - Quiver Quantitative
EU regulator backs Amneal’s Parkinson’s drug after Phase 3 data - Stock Titan
Does Amneal (AMRX) Joining Three Russell 2000 Defensive Indexes Recast Its Risk Profile? - simplywall.st
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Value-Defensive Index - marketscreener.com
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Form DEF 14A Amneal Pharmaceuticals Inc Class A For: 26 June - Investing.com UK
2DT Forecast — Price Target — Prediction for 2027 - TradingView
Amneal Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:AMRX) - TradingView
AMRX Forecast — Price Target — Prediction for 2027 - TradingView
Amneal Pharmaceuticals advances after securing FDA clearance for cancer treatment (AMRX) - MSN
Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD - Investing.com
Amneal Pharmaceuticals stock hits 52-week high at 16.62 USD By Investing.com - Investing.com South Africa
Rytvela from Amneal Pharmaceuticals Inc.biosimilar for chronic uveitis care - AD HOC NEWS
Amgen Inc. v. Amneal Pharm. LLC United States Court of Appeals of the Federal Circuit, 2020 945 F.3d 1368, 2020 - Sage Journals
Amneal Pharmaceuticals (AMRX) Stock Could Be 6% Below Fair Value After Its Sharp Rally - Sahm
Amneal (AMRX) agrees to buy Kashiv for $375M cash plus equity and milestones - Stock Titan
Amneal Pharmaceuticals Inc (AMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Amneal Pharmaceuticals Inc (AMRX) Institutional Confidence - TradingKey
Amneal Pharmaceuticals Inc (AMRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Amneal Pharmaceuticals Inc (AMRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Amneal Pharmaceuticals Inc - TradingKey
Amneal Pharmaceuticals, Inc. (AMRX) Latest Stock News & Headlines - Yahoo Finance
US progesterone supplies tighten as menopause treatment demand grows - Reuters
Amneal Pharmaceuticals Inc (AMRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Top 3 Health Care Stocks That May Collapse This Quarter - Benzinga
Amneal Pharmaceuticals (AMRX) Is Up 17.8% After CREXONT Phase 4 Gains And New Oncology Launch - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX), Elevance Health (ELV) and Tectonic Therapeutic (TECX) - The Globe and Mail
Amneal Pharmaceuticals, Inc. (AMRX) hits fresh high: Is there still room to run? - MSN
AMNEAL PHARMACEUTICALS, INC. (AMRX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Do options traders know something about Amneal stock we don't? - MSN
Amneal Pharmaceuticals stock hits 52-week high at 15.44 USD By Investing.com - Investing.com Nigeria
Is Amneal Pharmaceuticals Inc (AMRX) Overvalued After 4.4% Rally - GuruFocus
Dispensary of Hope Launches "Hope Alliance" Campaign with Suppor - GuruFocus
Amneal Pharmaceuticals stock hits 52-week high at 15.44 USD - Investing.com
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals - marketscreener.com
Why Amneal (AMRX) stock is trading up today - MSN
Amneal Pharmaceuticals bets on biosimilars, patches to power next growth phase - MSN
AMRX: Biosimilars, specialty launches, and strategic partnerships drive robust long-term growth - TradingView
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase - MarketBeat
Amneal and Pfizer GLP-1 Deal: New Growth Lever? - Yahoo Finance
Is Amneal a Buy Before Rytary Generic Erosion? - Yahoo Finance
What's Driving Amneal's 2026 Growth Outlook? - Yahoo Finance
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution - Pharmacy Practice News
Amneal Pharmaceuticals Inc (AMRX) 財務データ
収益
当期純利益
現金流量
EPS
2.10%
3.09%
大文字化:
|
ボリューム (24 時間):